Jazz Up Today Before Tomorrow's FDA Hearing, While Xoma Has Reverse Split

Logo of the U.S. Food and Drug Administration ...Image via Wikipedia By Val Brickates Kennedy, MarketWatch

BOSTON (MarketWatch) -- Shares of biotech group Xoma Ltd. spiked over 1,000% at market open Wednesday as the company conducted a 1-for-15 reverse stock split in order to boost its stock price to meet Nasdaq compliance rules.

For the next 20 trading sessions, Xoma will trade under the stock symbol XOMAD to reflect the split; after that time, the stock will revert back to its previous trading symbol of XOMA.

Xoma also announced that it has sold its royalty rights to the antibody treatment Cimzia for $4 million to an undisclosed buyer. The product, which is approved in the U.S. for the treatment of Crohn's disease and rheumatoid arthritis, is marketed by UCB S.A.

Shares of Xoma(XOMAD 3.68, -0.54, -12.82%), trading under its new symbol, were down 11% at $3.77.

Jazz Pharmaceuticals shares (JAZZ 11.37, +1.12, +10.93%) rallied after documents released by the U.S. Food and Drug Administration revealed that agency reviewers believe its drug candidate JZP-6 is effective in treating the pain condition fibromyalgia. The documents, however, also showed that they still have certain safety concerns about the medication.

The FDA released the documents ahead of an FDA advisory panel meeting on the product. The meeting is slated for Friday.

Shares of Jazz were up 15% at $11.74.

The NYSE Arca Pharmaceutical Index (DRG 290.37, +0.02, +0.01%) and the NYSE Arca Biotechnology Index (BTK 1,099, +0.01, +0.00%) were marginally lower at 289.95 and 1095.56, respectively.
Enhanced by Zemanta

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.